618061-76-0Relevant articles and documents
Compound, and preparation method and application thereof
-
Paragraph 0052-0057, (2017/08/30)
The invention relates to a compound, and a preparation method and application thereof. Specifically, the compound is as shown in a formula 1 which is described in the specification. The invention also provides the preparation method for the compound as shown in the formula 1. The preparation method comprises a step of contacting N-[4-[(3-chloro-4-fluorophenyl)amino]-7[[(3S)-tetrahydro-3-furyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butyleneamide with an alkaline aqueous solution in an organic solvent so as to obtain the compound as shown in the formula 1. The preparation method is simple to operate; a white powder product can be obtained through direct filtering after post-treatment; and the prepared compound has high purity, as high as 99% or above, and can be directly used as an impurity control substance for research on the quality of an afatinib bulk drug.
CRYSTALLINE FORMS OF AFATINIB DI-MALEATE
-
Paragraph 0095, (2015/07/16)
The present disclosure encompasses crystalline forms of Afatininb di-maleate and methods of their use.
PROCESS FOR PREPARING AMINOCROTONYLAMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES
-
Page/Page column 22-23, (2008/06/13)
The invention relates to an improved process for preparing aminocrotonylamino-substituted quinazoline derivatives of general formula (I) wherein the groups Ra, Rb, Rc and Rd have the meanings given in the claims, as well as sulphonyl derivatives of formula (XIII) and the use thereof as synthesis components for preparing quinazolines of formula (I). The quinazoline derivatives of formula (I) are inhibitors of signal transduction mediated by tyrosinekinases and by the Epidermal Growth Factor-Receptor (EGF-R) and are therefore particularly suitable for the treatment of tumoral diseases.
Process for preparing amino crotonyl compounds
-
Page/Page column 6, (2010/02/11)
The invention relates to an improved process for preparing 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylam ino)-1 -oxo-2-buten-1 -yl]am ino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline and related aminocrotonyl compounds and the preparation of a suitable salt of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1 -oxo-2-buten-1 -yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline for use as a pharmaceutically active substance.
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
-
Page/Page column 5, (2008/06/13)
The present invention relates to bicyclic heterocycles of general formula wherein Ra, Rb, Rc, Rd, Re and X are defined as in claim 1, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases and benign prostatic hyperplasia (BPH), diseases of the lungs and respiratory tract, and the preparation thereof.
BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF
-
Page 15, (2010/02/08)
The invention relates to bicyclic heterocycles of general formula (I), wherein Ra, Rb, Rc, Rd, Re, and X have the definitions indicated in claim 1, the tautomers, stereoisomers, mixtures, and salts thereof, especially the physiologically acceptable salts thereof containing inorganic or organic acids having valuable pharmaceutical properties, especially an inhibiting effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, especially cancer diseases and benign prostatic hyperplasia (BPH), diseases of the lungs and respiratory tract, and the production thereof.